GSK Sees Positive Trial Results For Potential Blockbuster Drug
Wall Street Journal
GSK said two late-stage trials of an asthma drug that could have peak sales of almost $4 billion met their goals.
Wall Street Journal
GSK said two late-stage trials of an asthma drug that could have peak sales of almost $4 billion met their goals.